SEC Form 4 · accession 0002092017-26-000007
Evommune, Inc. · EVMN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeegar Pravinkumar Patel
Officer — Chief Scientific Officer
Period of report
Jun 22, 2026
Accepted (ET)
Jun 24, 2026 · 8:00 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0002044725
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 22, 2026 | M | 1,488 | $3.84 | A | 47,891 | D | |
| Common Stock | Jun 22, 2026 | S | 1,488 | $22.50 | D | 46,403 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $3.84 | Jun 22, 2026 | M | 1,488 | D | — | May 11, 2033 | Common Stock | 1,488 | 27,842 | D |
Explanation of responses
- F1The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.
- F2One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.